Abstract:Candidate tumour suppressor ZMYND11 specifically recognizes histone K36 trimethylation on the histone variant H3.3 and helps regulate transcription elongation. This study identifies the PHD–bromo–PWWP cassette of the candidate tumour suppressor ZMYND11 as a specific 'reader' of trimethylated K36 on the histone variant H3.3. ZMYND11 seems to accumulate on gene bodies during transcription and functions in modulating transcription elongation. Structural and genomics experiments reveal the chromatin-binding properties of ZMYND11, and it is shown to be important for repressing transcription of genes linked to tumour cell growth. Recognition of modified histones by ‘reader’ proteins plays a critical role in the regulation of chromatin1. H3K36 trimethylation (H3K36me3) is deposited onto the nucleosomes in the transcribed regions after RNA polymerase II elongation. In yeast, this mark in turn recruits epigenetic regulators to reset the chromatin to a relatively repressive state, thus suppressing cryptic transcription2. However, much less is known about the role of H3K36me3 in transcription regulation in mammals. This is further complicated by the transcription-coupled incorporation of the histone variant H3.3 in gene bodies3. Here we show that the candidate tumour suppressor ZMYND11 specifically recognizes H3K36me3 on H3.3 (H3.3K36me3) and regulates RNA polymerase II elongation. Structural studies show that in addition to the trimethyl-lysine binding by an aromatic cage within the PWWP domain, the H3.3-dependent recognition is mediated by the encapsulation of the H3.3-specific ‘Ser 31’ residue in a composite pocket formed by the tandem bromo–PWWP domains of ZMYND11. Chromatin immunoprecipitation followed by sequencing shows a genome-wide co-localization of ZMYND11 with H3K36me3 and H3.3 in gene bodies, and its occupancy requires the pre-deposition of H3.3K36me3. Although ZMYND11 is associated with highly expressed genes, it functions as an unconventional transcription co-repressor by modulating RNA polymerase II at the elongation stage. ZMYND11 is critical for the repression of a transcriptional program that is essential for tumour cell growth; low expression levels of ZMYND11 in breast cancer patients correlate with worse prognosis. Consistently, overexpression of ZMYND11 suppresses cancer cell growth in vitro and tumour formation in mice. Together, this study identifies ZMYND11 as an H3.3-specific reader of H3K36me3 that links the histone-variant-mediated transcription elongation control to tumour suppression.

ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor–activated cancer

Global Characterization of Proteome and Lysine Methylome Features in EZH2 Wild-Type and Mutant Lymphoma Cell Lines.

ZMYND8 Reads the Dual Histone Mark H3K4me1-H3K14ac to Antagonize the Expression of Metastasis-Linked Genes.

Regulation of EZH2 by SMYD2-Mediated Lysine Methylation is Implicated in Tumorigenesis.

Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis

ZMYND 8 Acetylation Mediates HIF-dependent Breast Cancer Progression and Metastasis

A methylation-phosphorylation switch controls EZH2 stability and hematopoiesis

Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.

ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency

ZMYND11 Links Histone H3.3K36me3 to Transcription Elongation and Tumour Suppression.

Polycomb-independent Activity of EZH2 in Castration Resistant Prostate Cancer

Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer

EZH1/2 as targets for cancer therapy

The Noncanonical Role of EZH2 in Cancer.

EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells is Polycomb-Independent

Decreased Expression of EZH2 Reactivates RASSF2A by Reversal of Promoter Methylation in Breast Cancer Cells

Pcaf-Primed Ezh2 Acetylation Regulates Its Stability and Promotes Lung Adenocarcinoma Progression

No Easy Way Out for EZH2: Its Pleiotropic, Noncanonical Effects on Gene Regulation and Cellular Function

A Partially Disordered Region Connects Gene Repression and Activation Functions of EZH2

Chronic Myelogenous Leukemia – Initiating Cells Require Polycomb Group Protein EZH 2